Nuvalent Inc (NUVL) Issues Pipeline Update

Go back to Nuvalent Inc (NUVL) Issues Pipeline Update

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results

February 27, 2024 6:30 AM UTC

Well-capitalized with operating runway anticipated into 2027

CAMBRIDGE, Mass., Feb. 27, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline progress, reiterated key anticipated milestones and reported fourth quarter and full year 2023 financial results.

... More